Anti-Coagulants - Egypt

Egypt

The revenue in the Anti-Coagulants market in Egypt is estimated to reach US$37.06m in 2024.
It is expected to experience an annual growth rate (CAGR 2024-2029) of 9.51%, which will lead to a market volume of US$58.37m by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, with US$16,740.00m in 2024.
Egypt's market for anti-coagulants is witnessing a surge in demand due to the increasing prevalence of cardiovascular diseases in the country.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Egypt has been showing interesting developments in recent years.

Customer preferences: Egypt's population is aging, with an increasing number of people suffering from cardiovascular diseases. This has led to a growing demand for anti-coagulants, as they are commonly used in the treatment of these diseases. Additionally, there is a rising awareness of the importance of preventive healthcare, which has also contributed to the growth of the market.

Trends in the market: The Anti-Coagulants market in Egypt has been growing steadily in recent years, and this trend is expected to continue in the coming years. One of the key drivers of this growth is the increasing prevalence of cardiovascular diseases in the country. In addition, the market is also being driven by the rising demand for preventive healthcare, as well as the increasing availability of anti-coagulants in the market.

Local special circumstances: Egypt has a large population and a growing middle class, which has led to an increase in healthcare spending. Additionally, the government has been investing heavily in healthcare infrastructure in recent years, which has also contributed to the growth of the Anti-Coagulants market. However, there are also challenges in the market, such as the high cost of some anti-coagulants, which can limit their accessibility to some segments of the population.

Underlying macroeconomic factors: The Egyptian economy has been growing steadily in recent years, which has led to an increase in disposable income and healthcare spending. Additionally, the government has been implementing policies to improve the healthcare system, which has also contributed to the growth of the Anti-Coagulants market. However, there are also risks to the market, such as political instability and economic volatility, which can impact the overall healthcare industry in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.